Raynelle Mensah on AI in Pharma R&D: Integration Over Hype
Raynelle Mensah, COO - Life Sciences at Genesis Technology Management Group, brings a clear view to AI in pharmaceutical research. Her stance is simple: AI delivers value when it's integrated into existing work, guided by people who understand both scientists and regulators.
AI is not a side project. It becomes useful when it's part of a connected system, embedded in decisions teams make every day.
Grounded by Experience
Mensah's career spans clinical research strategy, program leadership, and enterprise operations. She has led cross-functional initiatives and built methods that connect day-to-day execution with long-range goals.
She keeps her work close to the bench and the review room. "My motivation for entering life sciences was never just about improving processes," she says. "Early on, I was exposed to the ethical side of medicine and regulation, and it showed me how much this field depends on protecting patients and upholding scientific integrity. That's what pulled me in and what keeps me committed to the work."
How Change Takes Hold in Pharma
This industry runs on rigor, precedent, and trust in proven methods. New tools earn their place by showing evidence and repeatable value.
Mensah puts it directly: "In this field, people build confidence through evidence. I believe real change happens when new approaches consistently show return on value to researchers and return on investment to the business. That's what helps teams trust and adopt them."
Recent industry outlooks echo this. Bold bets on AI matter, but practical adaptation to regulatory and economic realities determines whether those bets pay off.
Where AI Can Move the Needle
Mensah sees the upside in earlier, better decisions. AI can help teams decide which scientific paths deserve deeper investment, long before expensive studies lock in.
"When data is brought together with intention, it helps teams ask better questions sooner," she says. Across the sector, there's a shift from isolated pilots to enterprise platforms. Yet adoption is uneven, and the differentiator is clear: governance, regulatory alignment, and measurable ROI.
Time, Cost, and Smarter Acceleration
Drug development takes time because experimentation and review take time. The goal isn't speed for its own sake-it's clarity, earlier. That shortens cycles without cutting corners.
"What can ease this burden is thoughtful acceleration. But it must be guided by sound data and disciplined integration," Mensah notes. Shorter pathways free resources for more options while keeping scientific rigor intact, especially as late-stage attrition pressures R&D productivity.
Keep Speed Human-Centered
Mensah reframes the speed conversation around outcomes. "Faster development doesn't inherently diminish quality or the role of experts. It can actually allow for a greater focus on quality and for experts to benefit patients sooner by exploring more impactful solutions with less delay."
What R&D Leaders Can Do Now
- Define the decisions that matter. Map the questions where earlier certainty would change resourcing, protocol design, or portfolio focus.
- Get your data house in order. Standardize sources, track provenance, and make quality visible to scientists and QA-before you add new models.
- Embed AI into real workflows. Integrate with the tools teams already use; avoid stand-alone pilots that never touch production work.
- Set clear guardrails. Align with regulatory, biostatistics, and clinical leaders on validation plans, audit trails, and change control.
- Measure what matters. Tie impact to time-to-decision, protocol amendments avoided, site and patient burden, and attrition trends.
- Invest in shared language. Build transparency around data sources, model limits, and how results inform decisions-not replace experts.
- Upskill your teams. Focus on AI literacy, data integrity, and responsible use across functions. See practical options by job role at Complete AI Training.
A Practical Path Forward
Mensah's take is steady and usable: integration discipline, cultural fluency, and respect for human impact. Align AI with how researchers already work, make value measurable, and keep patients at the center.
Do that, and progress becomes consistent-less noise, more signal, and science that moves with confidence.
Your membership also unlocks:
